Quick Summary: Narayana Hrudayalaya Results
Quick Summary: Narayana Hrudayalaya Results
- Revenue: ₹21,512 Mn ↑ 61.2% YoY, ↑ 30.9% QoQ — driven by first-time consolidation of the UK acquisition from 6 Nov 2025 and steady India growth.
- EBITDA: ₹3,904 Mn (margin 18.2%); PAT: ₹1,281 Mn (margin 6.0%) — margins diluted as UK operates at lower profitability and integration costs kicked in.
- India ops revenue ₹15,004 Mn — ↑ 11.7% YoY but ↓ 4.5% QoQ; revenue per patient improved, volumes softened.
- Net debt: ₹22,321 Mn (Net D/E 0.53x), includes US$119 Mn and £150 Mn foreign currency debt — watch FX and interest costs.
Narayana Hrudayalaya Financial Highlights
– Consolidated operating revenue: ₹21,512 Mn (↑61.2% YoY; ↑30.9% QoQ)
– Consolidated EBITDA: ₹3,904 Mn; EBITDA margin: 18.2%
– Consolidated PAT: ₹1,281 Mn; PAT margin: 6.0%
– India operations revenue: ₹15,004 Mn (↑11.7% YoY; ↓4.5% QoQ)
– India hospitals EBITDA (incl. NHIC/NHIL/ATHMA/MEDHA): ₹2,506 Mn; margin: 21.2%
– NH Integrated Care & Insurance (NHIC + NHIL) EBITDA: ₹-134 Mn (drag on segment profitability)
– Net debt (Total borrowings less cash/investments): ₹22,321 Mn; Net D/E: 0.53x
– Cost mix for India hospitals (Q3 FY26): Consumables ~28%, Doctors & Nurses ~23%, Other manpower ~11%, Other expenses ~17%, Rent/Rev share ~2% of revenue
Why Key Numbers Changed (Important Insight)
– Revenue surge vs profit growth: The top line jumped as the UK network (13 facilities, 330 beds) was consolidated from 6 Nov 2025. This lifted revenue sharply, but UK units typically run at lower margins than India’s tertiary hospitals. Add initial integration costs and seasonality in India volumes, and you get a more modest rise at the EBITDA and PAT lines.
– Margins: Consolidated EBITDA margin at 18.2% reflects a mix shift toward UK and early-stage Integrated Care/Insurance losses (₹-134 Mn). India hospitals remain healthy (c. 21.2% margin), but consolidated margins compress when newer/overseas businesses are included.
– Profit vs revenue gap: PAT margin at 6.0% trails EBITDA because of higher depreciation/amortization (larger asset base post-acquisition) and finance costs (net debt ₹22.3 Bn, with USD/GBP borrowings). Currency swings can also affect interest and translation.
– One-time items: No specific one-offs were highlighted. The big driver is structural (first-time UK consolidation) rather than a one-time gain/loss.
– India QoQ dip: India revenue fell sequentially (↓4.5% total; ↓6.0% domestic), mainly on softer volumes. Importantly, revenue per patient improved, cushioning the impact.
Operational Performance & Business Trends
– Complex care stepping up:
– Bengaluru performed 244 robotic cardiac surgeries (↑35% QoQ) and 48 TAVIs (↑50% YoY).
– Howrah executed multiple complex pediatric cardiac interventions.
– Ahmedabad completed its first heart transplant in Dec-25.
These high-acuity procedures lift realisations and reinforce Narayana’s brand in cardiac/advanced care.
– India patient metrics:
– Average revenue per patient continued to rise YoY (helped by case mix and pricing).
– Footfalls (IP/OP) and ICU bed-days were softer QoQ, weighing on India revenue.
– Payor and business mix:
– Cardiac sciences remain the biggest specialty contributor (roughly a third), followed by oncology and neurosciences.
– Owned hospitals drive the majority of India revenue; insured and government scheme patients form a large share of payors; international patients contribute a single-digit share.
– UK integration:
– The UK platform adds scale and diversified geography but comes with a lower margin profile and initial integration friction. Expect operational streamlining and cross-learning to be margin levers over the next few quarters.
– Integrated Care & Insurance:
– Clinics footprint and transactions are ramping up from a small base. The segment is investing for growth (loss this quarter), but it can become a funnel for hospital admissions and a data/engagement engine over time.
Management Commentary (Simplified)
– We’re integrating the UK acquisition and see a bigger, more diversified Narayana as a result.
– India hospitals will keep focusing on complex procedures (robotics, TAVR/TAVI, transplants) to lift realisations and margins.
– Integrated Care and Insurance are long-term bets: short-term drag, long-term ecosystem benefits.
– Balance sheet is comfortable for growth; we’ll be disciplined on capex and strive to improve margins as integration stabilises.
Key Positives
- Strong consolidated growth from UK consolidation and steady India performance.
- Advanced cardiac and transplant capabilities deepening moat; ARPP improving.
- Healthy India hospital margins vs peers; cost structure under control.
- Balanced leverage (Net D/E 0.53x) leaves room for investment.
Key Concerns
- Margin dilution from lower-margin UK units during integration phase.
- Sequential softness in India volumes; recovery needs monitoring.
- Integrated Care/Insurance losses near term; timeline to breakeven uncertain.
- FX and interest-rate exposure from USD/GBP debt.
Final Takeaway for Investors
This is a scale-up quarter. The UK consolidation delivered a revenue step-up, while India hospitals stayed fundamentally sound but saw softer volumes QoQ. Near-term, expect margins to be lower than the historical India-only profile as the mix resets and new segments invest for growth. Medium term, if Narayana executes on UK integration, sustains complex procedure growth, and reins in start-up losses, margins should improve. Balanced stance: good structural story with execution and FX/integration risks to watch.
FAQs
– What is revenue?
Revenue is the total money earned from hospital services and related businesses before costs. Narayana’s Q3 FY26 revenue was ₹21,512 Mn.
– What is profit?
Profit (PAT) is what remains after all costs, interest, taxes, and depreciation/amortization. Q3 FY26 PAT was ₹1,281 Mn.
– Why did profit change differently from revenue?
Revenue jumped mainly due to UK consolidation. Profit grew less because UK margins are lower, integration and start-up losses (NHIC/NHIL at ₹-134 Mn) weighed on earnings, and finance/depreciation costs rose with a bigger asset base and higher debt.
– What happened to margins?
Consolidated EBITDA margin was 18.2%, lower than India hospitals’ c.21.2%, due to mix shift (UK), softer India volumes QoQ, and initial integration costs. As integration stabilises and volumes recover, margins can improve.
– Is it a good stock?
It depends on your risk and time horizon. Positives: strong franchise in complex care, expanding footprint, healthy balance sheet. Risks: near-term margin dilution, UK integration execution, FX exposure. Consider holding with a medium-term view if you believe management can lift margins post-integration.
Disclaimer
This post is for educational purposes only.
Indian Stock Results 